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1. Introduction
  Cerebral ischemia/reperfusion (I/R) injury during stroke is the third 
leading cause of death worldwide with a mortality rate approaching 
30% and a major cause of disability[1]. Much of the damage caused 
by cerebral IR injury is due to inflammatory processes affecting 
adjacent endothelial cell, neurons, and astrocytes, though the 
mechanisms associated with such inflammation have recently been 
characterized. In addition, increased plasma levels of neuropeptides 
(NP) following ischemic periods were shown to cause thrombosis or 
cerebral infarction. Inflammation may trigger leucocytes to release 
proteolytic enzymes, oxygen radicals, and active factors that alter 
TNF-毩 and IL-1毬 levels[2]. Thus, it is an urgent need to develop 
advanced treatments for inflammation in affected patients.
  Ferulic acid (FA), Puerarin(Pr) and Astragaloside(Al) are effective 
components in many natural medicine, and they were commonly 
Objective: To investigate the effects of the active ingredients combined therapy on 
inflammatory factors interleukin 1 beta (IL-1毬) and neuropeptide Y (NPY) based on 
pharmacodynamics in rats. Methods: The animal model was built by transient middle cerebral 
artery occlusion (MCAO). The method for evaluating the concentrations of the FA-Pr-Al 
components in rat plasma was established by using HPLC and the expression levels of IL-1毬 
and NPY were determined by ELISA. A new mathematics method of the trend of percentage 
rate of change (PRC) was used to assess the correlation between pharmacokinetics (PK) and 
pharmacodynamics (PD). Results: FA-Pr-Al in combination reduced neurological deficits, 
decreased infarct volume and inhibited the expression levels of IL-1毬and NPY (all P<0.05) 
compared with the model group. FA, Pr and Al all displayed two compartment open models 
in rats. Clockwise hysteresis loops were obtained by time-concentration-effect curves. IL-1毬
and NPY level changes in the plasma followed an opposite trend to the plasma concentration 
tendency after Cmax was reached. Astragaloside’s PRC value was significantly higher than those 
of FA and puerarin between 120 to 180 min. Conclusions: The pharmacokinetics of FA-Pr-
Al in combination were closely related its pharmacodynamics in treating ischemia/reperfusion 
injury, and the components of FA-Pr-Al may have a synergistic pharmacological effect. 
Astragaloside may play a more pronounced role in regulating IL-1毬and NPY levels compared 
with puerarin or FA.
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used for treating I/R injury in the clinical[3]. Due to the complex 
chemical composition of natural medicine ,classical quality 
control measures and characterization methods (pharmacokinetic/
pharmacodynamic, PK/PD) applied to purified chemical drugs 
were often not suited for the[4]. How to determine the effective 
components’ action has become an important factor hindering 
the development of natural products[5]. Multiple studies have 
been recently focused on correlations between PK/PD and dose, 
concentration and time, which not only describe and predict the 
effects of a drug, but also can explore the mechanism of action of 
effective drugs[6].
  The current study aimed to assess the correlation between 
pharmacokinetics of FA-Pr-Al components and levels of the 
inflammatory factors IL-1毬 and neuropeptide Y (NPY) with a new 
mathematical analysis in the I/R rat model induced by transient 
middle cerebral artery occlusion (MCAO). 
2. Materials and methods
2.1. Animals 
  Forty adult male Sprague-Dawley rats weighing (280 依 20) g were 
purchased from the Animal Center of Zhejiang University (China, 
laboratory animal certificate: scxk 2008-0115). Animal care and 
surgical procedures were performed in accordance with National 
Institute of Health Guidelines (1996; NIH Publication No. 80-23).
2.2. Focal cerebral ischemia-reperfusion rat model induced 
by MCAO
  Rats were randomly subdivided in sham group (negative control), 
cerebral I/R damage group (model), cerebral I/R damage with 
FA-Pr-Al treatment (treatment group) and cerebral I/R damage 
with nimodipine treatment group (positive group) by 10 rats 
in each group. At a given time point, rats were anesthetized by 
intraperitoneal (ip.) injection of 10% chloral hydrate (0.4 mL/100 
g body weight). Cerebral I/R was induced by MCAO using 
intraluminal filament threads. After maintaining 60-min right 
MCAO (ischemia), MCA blood flow was restored by withdrawal 
of nylon sutures[7]. Sham treatment was performed in the same way 
but without inserting threads. Dead rats and the rats if determined 
as skull base hemorrhage by autopsy were excluded from the 
experiment. 
2.3. FA-Pr-Al treatment
  Ferulic acid (Lot No.11773-201211), puerarin (Lot No.130752-
201209), astragaloside IV (Lot No. 140781-201113) and nimodipine 
(Lot No.18659-201207) were purchased from the National Institute 
for the Control of Pharmaceutical and Biological Products. The ratio 
of components of FA-Pr-Al was 1:64:28 according to clinical dose 
equivalen conversion, and then diluted with normal saline into 2.5 g/
mL. Rats in the IR+FA-Pr-Al group were orally administered with 
single-dose of 4.0 g/kg within 30 s after MCAO, while the dose of 
IR+ nimodipine group was 10 mg/kg. Sham control and I/R model 
animals were treated each with an equivalent volume of normal 
saline.  
2.4. Pharmacokinetic studies
  Blood samples (about 500 毺L at every time) collected via the 
carotid artery at 0, 5, 15, 30, 60, 120, 180, 240 and 360 min after 
FA-Pr-Al administration was mixed with 4% trisodium citrate (1:9) 
and then centrifugated 15 min at 5 000 rpm. The samples were 
used to detect drug concentration by the methods of HPLC, and to 
detect the expression of IL-1毬and NPY by the methods of ELISA. 
Pharmacokinetics parameters of the FA-Pr-Al components were 
computed using the DAS 2.0 software (Chinese Pharmacologic 
Society, Beijing, China)[8]. 
2.5. HPLC analysis of FA-Pr-Al constituents 
  HPLC separation was performed on an Agilent 1200 system 
(Agilent Technologies, USA). FA and Pr were detected using Agilent 
TC-C18 chromatography column (4.6 mm伊150 mm; 5 毺m); the 
mobile phase was 3% methanol with 3% acetic acid (32:68, v/v) 
mixture, used at a flow rate of 1.0 mL/min at 25 曟. The injection 
volume was 10 毺L, and detection was made at 323 nm and 250 
nm, respectively. Al was detected by HPLC with Alltech3300 ELSD 
detector, on Zorbax SB-C18 chromatography column (250 mm伊
4.6 mm; 5 毺m). The mobile phase was acetonitrile: water (33:67, 
v/v) used in a drift tube at 100 曟 (1.0 mL/min flow rate) with 
2.0 L/min carrier gas (Pei et al, 2011). 7-hydroxyl coumarin (Lot 
No. 121739-201001), P-hydroxybenzoic acid (Lot No. 110648-
201018), and digoxin (Lot No. 100080- 201006) were used as 
internal standards for FA, Pr, and Al, respectively. The results were 
analyzed by the SPSS 11.5 statistical software. Validation of the 
HPLC assay involved assessing linearity, sensitivity, precision, 
accuracy, and precision profiles of FA, Pr and Al under various 
conditions. Selectivity of elution conditions was examined by 
comparing chromatograms of blank rat plasma from six different 
rats. Sensitivity was represented by lower limit of quantification 
(LLOQ), defined as a signal to noise ratio of 3:1. Linear regression 
was analyzed using GraphPad Prism 5, version 5.03 for Windows 
(GraphPad Software, San Diego, CA, USA) by the least sum-of-
squares method.
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2.6. Determination of IL-1毬 and NPY plasma levels
  The levels of IL-1毬 and NPY in rats‘ plasma were analyzed on an 
automatic enzyme immunoassay instrument (Hamilton Bonaduz AG, 
Model F.A.M.E.16/30, Switzerland) using ELISA kits (Santa Cruz 
Biotechnology Inc., USA). Guided by the manufacturer’s protocol, 
the detection wavelength was at 450 nm.
2.7.  Pharmacokinetics and pharmacodynamics correlation 
analysis 
  Compared with single component drugs, more complexity is 
expected for the pharmacokinetics and pharmacodynamics of 
FA-Pr-Al. To elucidate the correlation of pharmacokinetics and 
pharmacodynamics, the trend chart of Percentage Rate of Change 
(PRC%) was drawn according to the following formula with 
PRC%=(T2-T1)/T1伊100%, at appropriate intervals between two 
pharmacokinetic and pharmacodynamic points. Time-concentration-
effect curves for FA, Pr, and Al were established with MATLAB 
7.0 software (MathWorks, New Mexico, USA). The correlation of 
pharmacokinetics and pharmacodynamics were analyzed by both 
trend chart and Time-concentration-effect curves, based on the same 
type of compartment model with FA-Pr-Al components. 
2.8. Neurological evaluation
  Neurological deficits were evaluated 24 h after reperfusion. 
Neurologic findings were scored on a 5-point scale (0: no deficit; 1: 
mild deficit-failure of left forepaw extension; 2: moderate deficit-
circling to the left; 3: severe deficit-falling to the left; or 4: critical 
deficit-depressed consciousness, no spontaneous walking).
2.9 .  Hi s to log ica l  in farc t  s i z e  de t e rminat ion  by 
triphenyltetrazolium chloride staining
  Rats were euthanized by cervical dislocation, and brains were 
excised; five brain tissue samples for each group were coronally 
sliced (2 mm thickness) on a freezing microtome and stained with 
2% 2,3,5-triphenyltetrazolium chloride (TTC) at 37 曟 in the dark 
for 30 min to demarcate the infarct area. Rostral and caudal slices 
were photographed and analyzed using a digital image analysis 
system (Sigma Scan Pro, SPSS, Chicago, IL, USA) to indirectly 
estimate infarct area and volume. Infarct volume (%) was determined 
as follows: 
Infarct volume (%) = (Vipsilateral - Vcontralateral)/Vcontralateral伊100% 
2.10. Statistical analysis
  All data were expressed as mean 依 standard deviation (SD). 
Statistical analyses were performed with the SPSS 11.5 statistical 
software. One-way analysis of variance (ANOVA) and LSD post 
hoc methods were used to determine the significance of data sets. P 
values < 0.05 were considered statistically significant. 
3. Results
3.1. Neurological deficits
More severe neurological deficits were observed in the model group 
compared with animals of the sham group at 24 h. The scores of 
neurological deficits in animals treated with FA-Pr-Al or nimodipine 
exhibited significantly less when compared with the model group 
(Table 1).
Table 1 
FA-Pr-Al effects on neurological deficit at 24 h after reperfusion.
Group dose n Neurologic score
Sham group NS 10 0.20依0.18
Model group NS  7      2.80依0.15ΔΔ
FA-Pr-Al group 4 g/kg  8         1.50依0.20**ΔΔ
Nimodipine group 10 mg/kg  8         1.40依0.27**ΔΔ
ΔΔP < 0.01 vs. sham group;  **P<0.01 vs. model group.
3.2. Infarct volume
  Infarct volume was significantly greater in the model group 
compared with sham animals (P<0.01). Quitely different with the 
model group, infarct volumes in FA-Pr-Al treatment rats exhibited 
significantly decreased ,and the similar result were observed from 
the positive control group (Figure 1).
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Figure 1. Effects of FA-Pr-Al on infarct volume in a rat model of cerebral 
ischemia/reperfusion (I/R).
TTC leaves infarcted tissue unstained (white), while viable tissue is stained 
(red).  
ΔP<0.05, ΔΔP<0.01 vs. sham group; *P<0.05, **P<0.01 vs. model group. 
Positive control: Nimodipine group.
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3.3. IL-1毬 and NPY levels
  The expression levels of IL-1毬 and NPY were increased in 
model group rats’ plasma compared with sham animals at all time 
points (all P<0.01),while the levels in FA-Pr-Al treatment group 
were decreased significantly at 60, 120, 180, 240, and 360 min (all 
P<0.01; Figure 2). 
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Figure 2. Effects of FA-Pr-Al on plasma NPY and IL-1毬 levels in a rat 
model of I/R. NPY and IL-1毬 levels were determined by ELISA. 
(A) Plasma IL-1毬 levels. (B) Plasma NPY levels . 
ΔP<0.05, ΔΔP< 0.01 vs. 
sham group; *P<0.05, ** P<0.01 vs. model group. IL-1毬: Interlueikin-1 
beta; NPY: Neuropeptide Y. 
3.4. Chromatographic separation and determination of  FA-
Pr-Al components
  Typical chromatograms of FA demonstrated an average recovery 
(n=6) of 96.41% (RSD=2.36%), with FA and 7-hydroxyl coumarin 
peaks clearly separated, with retention times of 6.6 and 5.8 min, 
respectively. Meanwhile, typical chromatograms of puerarin 
demonstrated an average recovery (n=6) of 94.84% (RSD=3.63%), 
with puerarin and p-hydroxybenzoic acid peaks clearly separated, 
with retention times about 7.2 and 5.5 min, respectively. Typical 
chromatograms of astragaloside demonstrated an average recovery 
(n=6) of 90.54% (RSD=5.05%), denoting clearly that separated 
astragaloside and digoxin peaks with retention times was about 8.2 
and 3.8 min, respectively.
3.5. Pharmacokinetic parameter determination of FA-Pr-Al 
components
  Pharmacokinetic parameters of ferulic acid, puerarin and 
astragaloside were summarized in (Table 2). The pharmacokinetic 
profiles of the three compounds (FA, Puerarin and Astragaloside) 
administered orally displayed typical bi-exponential decline; their 
plasma concentration-time data were fitted into classical two-
compartment first-order open model (C= A.e-毩
.t + B.e-毬
.t ) using a 
weighting factor of 1/y2 which can make them have the same type of 
metabolism in rats after a single oral administration of FA-Pr-Al (4.0 
g/kg) (Figure 3).
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Figure 3. Plasma concentrations of the ferulic acid, puerarin, and 
astragaloside over time. 
Plasma samples were harvested from rats in each group at the time points 
indicated. The concentrations of components were determined by HPLC. The 
mean 依 SD was shown for each time point.
Table 2
Pharmacokinetic parameters of the ferulic acid, puerarin and astragaloside in rats after oral administration of FA-Pr-Al (4 g/kg) after MCAO 
(means 依SD) (n=6).
Parameter Ferulic acid Puerarin Astragaloside
AUC(0-t) (min伊mg/L) 405.4依60.1 422.6依64.4    1 741.2依145.6
AUC(0-曓) (min伊mg/L) 775.8依59.4   795.0依127.5    1 977.1依153.2
t1/2z (min) 333.2依79.8 510.7依48.6   104.5依2.6
CLz/F (L/min/kg)   0.026依0.001   0.017依0.002       0.010依0.001
Vz/F (L/kg) 12.4依3.3 12.9依3.1       1.5依0.2
Cmax (mg/L)  1.6依0.3  1.6依0.1     11.0依0.5
Tmax(min) 15 30 60
Notes: AUC was determined as area under the concentration versus time curve; Cmax, maximal concentration; Tmax was determined as the time 
when the maximal concentration reached; CLz/F, clearance; Vz/F, apparent volume of distribution; t1/2z ; terminal half-life.
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3.6. Time-concentration-effect curves
  At the time points, concentration and effect did not display a strict 
one-to-one correspondence after oral administration. One plasma 
concentration of FA-Pr-Al corresponded to two kinds of efficacy, and 
maximal effects were lagged behind peaks of plasma concentration. 
Notably, the time-concentration-effect curves were anticlockwise 
hysteresis loops between the plasma concentration of Ferulic acid 
and the levels of IL-1毬 and NPY. However, clockwise hysteresis 
loops were obtained for time-concentration-effect curves between 
puerarin and astragaloside plasma concentrations and the levels of 
IL-1毬 and NPY (Figure 4).
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Figure 4. Relationship between plasma concentrations of the ferulic acid, 
puerarin, and astragaloside, and plasma efficacy by IL-1毬 and NPY levels. 
  Arrows indicate the direction of time. (a) plasma FA and IL-1
毬 contents; (b) plasma puerarin and IL-1毬 contents; (c) plasma 
astragaloside and IL-1毬 contents; (d) plasma FA and NPY contents; 
(e) plasma puerarin and NPY contents; (f) plasma astragaloside and 
NPY contents.
3.7. Pharmacokinetic and pharmacodynamic correlation 
analysis
  Compared with the PRC values for IL-1毬 and NPY plasma 
levels, the plasma concentration change tendency in PRC of FA-
Pr-Al components were the opposite direction after the time 
corresponding to the Cmax. The PRC value obtained for astragaloside 
was significantly higher than what observed for FA and Pr at the fifth 
point of time, between 120 to 180 min. These results suggested that 
astragaloside may play a more pronounced role in regulating IL-1毬 
and NPY levels, compared with puerarin or FA (Figure 5).
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Figure 5. PRC( %) between two pharmacokinetic or pharmacodynamic 
points.
The PRC was derived with the formula of (T2-T1)/T1暳100%.
 △T1 represents 
two points from 5 min to 15 min of pharmacokinetics or pharmacodynamics 
respectively. △T2 represents from 15 min to 30 min. △T3 represents from 
30 min to 60 min. △T4 represents from 60 min to 120 min. △T5 represents 
from 120 min to 180 min. △T6 represents from 180 min to 240 min. △T7 
represents from 240 min to 360 min. 
4. Discussion
  Several nature medicine products have been shown to exert 
protective effects against cerebral ischemia-reperfusion injury such 
as Salvianolate, hydroxy Safflower Pigment A, breviscapin, and 
ligustrazine. These products achieved neuroprotection through 
various mechanisms, including upregulating the expression of heat 
shock protein 22, phosphorylated protein kinase B, transforming 
growth factor-毬1, and GM130 as well as activation of PI3K/Akt 
and the Nrf2 signaling pathway[10]. 
  In this study, we demonstrated that animals treated with FA-Pr-
Al exhibited significantly less severe neurological deficits and 
decreased infarct volumes. At the molecular, these effects were 
accompanied by markedly decreased IL-1毬 and NPY, indicating a 
neuroprotective effect for FA-Pr-Al after I/R injury. 
  Next, we obtained blood drug concentration of FA, Pr and Al in FA-
Pr-Al in combination as well as IL-1毬 and NPY in rats at different 
time points by pharmacokinetics and pharmacodynamics. However, 
the results of the time-concentration-effect curves and compartmental 
models suggested that FA-Pr-Al may affect not only local cerebral 
tissues, but also a wide variety of systemic organs and tissues. 
Because of time lag of blood drug concentration, it is difficult to 
directly analyze the relationship between the pharmacokinetics and 
pharmacodynamics[11]. 
  We have studied the correlation of pharmacokinetic and 
pharmacodynamic on FA-Pr-Al, based on the analysis of the 
change tendency in PRC values for plasma FA-Pr-Al component 
concentrations as well as plasma IL-1毬 and NPY levels, so 
as to determine the effect of individual components on drug 
pharmacodynamics. PRC represents the metabolic rate of change 
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over a period of time. This formula of PRC is a new mathematical 
analysis method, which allows a more intuitive description of the 
correlation of PD/PK and helps us to determine the components that 
affect certain pharmacodynamic parameters from the cure graph. 
From the trend chart the astragaloside metabolic rate decreased 
at a more pronounced level compared with FA and puerarin after 
blood concentration peaked, while pharmacodynamics of IL-1毬 
and NPY levels showed negligible changes in rats at the same time. 
It is obvious that the opposite tendency between the changes of 
blood FA-Pr-Al component concentration correlates with efficacy, 
especially, the change of PRC from the third to sixth value for FA, 
and the change of PRC from the fourth to sixth value for puerarin 
and astragaloside. These findings indicate the fast nature medisine 
metabolism and its obvious effects. According to the trend chart, 
it appears that the three components in FA-Pr-Al may play a 
synergistic pharmacodynamic effect. Indeed, emerging evidence has 
suggested that multiple compounds from herbals might demonstrate 
synergism. The concentration changes of astragaloside noticeably 
accelerated from the fourth to sixth value, while the change in IL-1
毬 levels was also evident. These results suggest that IL-1毬 may be 
a target of astragaloside or the latter may play a major role in IL-1 毬 
homeostasis. Nevertheless, the change on the levels of NPY was not 
significant, suggesting that NPY may not a target of astragaloside, 
FA or puerarin. 
  This research was completed according to the “nature medicine 
indications Pharmacokinetics” guiding principles[12]. The idea 
was to identify the role of the compound in vivo and the metabolic 
mechanisms associated with the drug ingredients. This has been 
done by quantitatively describing the composition and efficacy 
in combination with the appropriate mathematical methods for 
assessing the relationship between them and the existing law. This 
mathematical method for PK-PD analysis allowed the identification 
of high correlation ingredients,thus the pharmaceutical ingredients 
obtained may be regarded as “indications of ingredients.” 
Furthermore, this mathematical method used for PK / PD analysis 
may also strongly correlate with unknown components, suggesting 
that the medicine may have other not yet detected component with 
strong pharmacological activity. 
  In FA-Pr-Al, the diverse components may have a synergistic 
pharmacological effect, which may be typical of nature medicine 
and its merits will be further investigated. Furthermore, astragaloside 
may play a more pronounced role in regulating IL-1毬 and NPY 
levels compared with puerarin or FA. The mathematical method can 
be used to find a strong correlation ingredient for PK-PD analysis.
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